WALTHAM, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. TSRO, an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2015 Multinational Association of Supportive Care in Cancer (MASCC/ISOO) Annual Meeting, June 25 to 27, 2015, in Copenhagen.
Presentation Details:
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly- or moderately emetogenic chemotherapy (HEC; MEC)
Abstract: 11-03-O, Oral Presentation, Friday, June 26, 2015 from 5:45 PM to 7:15 PM
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC)
Abstract: 11-38-P, Poster Presentation, Friday, June 26, 2015
Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline/cyclophosphamide (A/C) moderately emetogenic therapy (MEC)
Abstract: 11-39-P, Poster Presentation, Friday, June 26, 2015
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) using anthracycline-cyclophosphamide (AC)-based chemotherapy
Abstract: 11-11-P, Poster Presentation, Friday, June 26, 2015
Pharmacokinetics of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy volunteers
Abstract: 11-20-P, Poster Presentation, Friday, June 26, 2015
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of rolapitant, a novel NK-1 receptor antagonist
Abstract: 11-07-P, Poster Presentation, Friday, June 26, 2015
Rolapitant is an investigational product candidate that has not been approved by any regulatory agency.
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.